About the Study

Acute Myeloid Leukemia (AML): A clinical study of enasidenib to treat relapsed/refractory AML with IDH-2 mutations

The overall goal of this study is to find out what effects, good and/or bad, enasidenib has on children and adolescents with AML with IDH2 mutations. This study is for patients who are 2 to 18 years old.

Interested in learning more?

Full Study Name: ADVL18P1 -An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation